Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Murumägi A[au]:

Search results

Items: 25

1.

Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy.

Lepikhova T, Karhemo PR, Louhimo R, Yadav B, Murumägi A, Kulesskiy E, Kivento M, Sihto H, Grénman R, Syrjänen SM, Kallioniemi O, Aittokallio T, Wennerberg K, Joensuu H, Monni O.

Mol Cancer Ther. 2018 Sep;17(9):2060-2071. doi: 10.1158/1535-7163.MCT-17-0733. Epub 2018 Jul 3.

PMID:
29970484
2.

Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma.

Karvonen H, Chiron D, Niininen W, Ek S, Jerkeman M, Moradi E, Nykter M, Heckman CA, Kallioniemi O, Murumägi A, Ungureanu D.

Blood Adv. 2017 Nov 9;1(24):2257-2268. doi: 10.1182/bloodadvances.2017010215. eCollection 2017 Nov 14.

3.

Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies.

Sveen A, Bruun J, Eide PW, Eilertsen IA, Ramirez L, Murumägi A, Arjama M, Danielsen SA, Kryeziu K, Elez E, Tabernero J, Guinney J, Palmer HG, Nesbakken A, Kallioniemi O, Dienstmann R, Lothe RA.

Clin Cancer Res. 2018 Feb 15;24(4):794-806. doi: 10.1158/1078-0432.CCR-17-1234. Epub 2017 Dec 14.

PMID:
29242316
4.

Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors.

Kolberg M, Bruun J, Murumägi A, Mpindi JP, Bergsland CH, Høland M, Eilertsen IA, Danielsen SA, Kallioniemi O, Lothe RA.

Mol Oncol. 2017 Sep;11(9):1156-1171. doi: 10.1002/1878-0261.12086. Epub 2017 Jul 5.

5.

Targeting ROR1 identifies new treatment strategies in hematological cancers.

Karvonen H, Niininen W, Murumägi A, Ungureanu D.

Biochem Soc Trans. 2017 Apr 15;45(2):457-464. doi: 10.1042/BST20160272. Review.

PMID:
28408486
6.

Consistency in drug response profiling.

Mpindi JP, Yadav B, Östling P, Gautam P, Malani D, Murumägi A, Hirasawa A, Kangaspeska S, Wennerberg K, Kallioniemi O, Aittokallio T.

Nature. 2016 Nov 30;540(7631):E5-E6. doi: 10.1038/nature20171. No abstract available.

PMID:
27905421
7.

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML.

Malani D, Murumägi A, Yadav B, Kontro M, Eldfors S, Kumar A, Karjalainen R, Majumder MM, Ojamies P, Pemovska T, Wennerberg K, Heckman C, Porkka K, Wolf M, Aittokallio T, Kallioniemi O.

Leukemia. 2017 May;31(5):1187-1195. doi: 10.1038/leu.2016.314. Epub 2016 Nov 11.

8.

Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling.

Brunen D, García-Barchino MJ, Malani D, Jagalur Basheer N, Lieftink C, Beijersbergen RL, Murumägi A, Porkka K, Wolf M, Zwaan CM, Fornerod M, Kallioniemi O, Martínez-Climent JÁ, Bernards R.

Oncotarget. 2016 Jun 21;7(25):37407-37419. doi: 10.18632/oncotarget.9822.

9.

Drug response prediction by inferring pathway-response associations with kernelized Bayesian matrix factorization.

Ammad-Ud-Din M, Khan SA, Malani D, Murumägi A, Kallioniemi O, Aittokallio T, Kaski S.

Bioinformatics. 2016 Sep 1;32(17):i455-i463. doi: 10.1093/bioinformatics/btw433.

PMID:
27587662
10.

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies.

Yadav B, Pemovska T, Szwajda A, Kulesskiy E, Kontro M, Karjalainen R, Majumder MM, Malani D, Murumägi A, Knowles J, Porkka K, Heckman C, Kallioniemi O, Wennerberg K, Aittokallio T.

Sci Rep. 2014 Jun 5;4:5193. doi: 10.1038/srep05193.

11.

Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.

Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, Almusa H, Bespalov MM, Ellonen P, Elonen E, Gjertsen BT, Karjalainen R, Kulesskiy E, Lagström S, Lehto A, Lepistö M, Lundán T, Majumder MM, Marti JM, Mattila P, Murumägi A, Mustjoki S, Palva A, Parsons A, Pirttinen T, Rämet ME, Suvela M, Turunen L, Västrik I, Wolf M, Knowles J, Aittokallio T, Heckman CA, Porkka K, Kallioniemi O, Wennerberg K.

Cancer Discov. 2013 Dec;3(12):1416-29. doi: 10.1158/2159-8290.CD-13-0350. Epub 2013 Sep 20.

12.

Aneuploidy facilitates oncogenic transformation via specific genetic alterations, including Twist2 upregulation.

Högnäs G, Hämälistö S, Rilla K, Laine JO, Vilkki V, Murumägi A, Edgren H, Kallioniemi O, Ivaska J.

Carcinogenesis. 2013 Sep;34(9):2000-9. doi: 10.1093/carcin/bgt171. Epub 2013 May 20.

PMID:
23689353
13.

Reanalysis of RNA-sequencing data reveals several additional fusion genes with multiple isoforms.

Kangaspeska S, Hultsch S, Edgren H, Nicorici D, Murumägi A, Kallioniemi O.

PLoS One. 2012;7(10):e48745. doi: 10.1371/journal.pone.0048745. Epub 2012 Oct 31.

14.

Cytokinesis failure due to derailed integrin traffic induces aneuploidy and oncogenic transformation in vitro and in vivo.

Högnäs G, Tuomi S, Veltel S, Mattila E, Murumägi A, Edgren H, Kallioniemi O, Ivaska J.

Oncogene. 2012 Aug 2;31(31):3597-606. doi: 10.1038/onc.2011.527. Epub 2011 Nov 28.

15.

DNA methylation signatures of the AIRE promoter in thymic epithelial cells, thymomas and normal tissues.

Kont V, Murumägi A, Tykocinski LO, Kinkel SA, Webster KE, Kisand K, Tserel L, Pihlap M, Ströbel P, Scott HS, Marx A, Kyewski B, Peterson P.

Mol Immunol. 2011 Dec;49(3):518-26. doi: 10.1016/j.molimm.2011.09.022. Epub 2011 Oct 27.

PMID:
22036612
16.

Identification of fusion genes in breast cancer by paired-end RNA-sequencing.

Edgren H, Murumagi A, Kangaspeska S, Nicorici D, Hongisto V, Kleivi K, Rye IH, Nyberg S, Wolf M, Borresen-Dale AL, Kallioniemi O.

Genome Biol. 2011;12(1):R6. doi: 10.1186/gb-2011-12-1-r6. Epub 2011 Jan 19.

17.

Genome-wide RNA interference in Drosophila cells identifies G protein-coupled receptor kinase 2 as a conserved regulator of NF-kappaB signaling.

Valanne S, Myllymäki H, Kallio J, Schmid MR, Kleino A, Murumägi A, Airaksinen L, Kotipelto T, Kaustio M, Ulvila J, Esfahani SS, Engström Y, Silvennoinen O, Hultmark D, Parikka M, Rämet M.

J Immunol. 2010 Jun 1;184(11):6188-98. doi: 10.4049/jimmunol.1000261. Epub 2010 Apr 26.

18.

Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes.

Kisand K, Link M, Wolff AS, Meager A, Tserel L, Org T, Murumägi A, Uibo R, Willcox N, Trebusak Podkrajsek K, Battelino T, Lobell A, Kämpe O, Lima K, Meloni A, Ergun-Longmire B, Maclaren NK, Perheentupa J, Krohn KJ, Scott HS, Husebye ES, Peterson P.

Blood. 2008 Oct 1;112(7):2657-66. doi: 10.1182/blood-2008-03-144634. Epub 2008 Jul 7.

19.

Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1).

Ströbel P, Murumägi A, Klein R, Luster M, Lahti M, Krohn K, Schalke B, Nix W, Gold R, Rieckmann P, Toyka K, Burek C, Rosenwald A, Müller-Hermelink HK, Pujoll-Borrell R, Meager A, Willcox N, Peterson P, Marx A.

J Pathol. 2007 Apr;211(5):563-71.

PMID:
17334980
20.

Ets transcription factors regulate AIRE gene promoter.

Murumägi A, Silvennoinen O, Peterson P.

Biochem Biophys Res Commun. 2006 Sep 22;348(2):768-74. Epub 2006 Jul 31.

PMID:
16890195
21.

Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1.

Meager A, Visvalingam K, Peterson P, Möll K, Murumägi A, Krohn K, Eskelin P, Perheentupa J, Husebye E, Kadota Y, Willcox N.

PLoS Med. 2006 Jul;3(7):e289.

22.

Cooperative activation of transcription by autoimmune regulator AIRE and CBP.

Pitkänen J, Rebane A, Rowell J, Murumägi A, Ströbel P, Möll K, Saare M, Heikkilä J, Doucas V, Marx A, Peterson P.

Biochem Biophys Res Commun. 2005 Aug 5;333(3):944-53.

PMID:
15964547
23.

Selective loss of regulatory T cells in thymomas.

Ströbel P, Rosenwald A, Beyersdorf N, Kerkau T, Elert O, Murumägi A, Sillanpää N, Peterson P, Hummel V, Rieckmann P, Burek C, Schalke B, Nix W, Kiefer R, Müller-Hermelink HK, Marx A.

Ann Neurol. 2004 Dec;56(6):901-4.

PMID:
15562414
24.

Autoimmune regulator induced changes in the gene expression profile of human monocyte-dendritic cell-lineage.

Sillanpää N, Magureanu CG, Murumägi A, Reinikainen A, West A, Manninen A, Lahti M, Ranki A, Saksela K, Krohn K, Lahesmaa R, Peterson P.

Mol Immunol. 2004 Nov;41(12):1185-98.

PMID:
15482854
25.

Characterization of regulatory elements and methylation pattern of the autoimmune regulator (AIRE) promoter.

Murumägi A, Vähämurto P, Peterson P.

J Biol Chem. 2003 May 30;278(22):19784-90. Epub 2003 Mar 21.

Supplemental Content

Loading ...
Support Center